President Trump's trade policies are sending many stocks that were performing well in the wrong direction and exacerbating things for others that were already struggling. So, the time seems ripe for investors to look for bargains.However, not every beaten-down stock is worth investing in -- many look more like value traps than anything else, no matter how low their share prices have fallen. Consider two examples: Tilray (TLRY -2.65%) and Novavax (NVAX 4.81%). Both companies are trading well below $10 due to ...

Group 1: Novavax Stock Performance - Novavax (NVAX) shares increased by 11.4% to close at $6.24, following a significant trading volume compared to normal sessions, despite a 28.8% loss over the past four weeks [1][2] - The stock price recovery is attributed to a rebound after an 8-session decline, with investors optimistic about a favorable FDA decision regarding the company's protein-based COVID-19 vaccine [2] Group 2: Financial Expectations - Novavax is projected to report a quarterly loss of $0.43 per share, reflecting a year-over-year increase of 59.1%, while revenues are expected to be $72.27 million, down 23% from the previous year [3] - The consensus EPS estimate for Novavax has been revised 7.6% higher in the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [4] Group 3: Industry Context - Novavax operates within the Zacks Medical - Biomedical and Genetics industry, where another company, Travere Therapeutics (TVTX), experienced a 9.5% decline to $14.99, with a -12.6% return over the past month [4] - Travere's consensus EPS estimate remains unchanged at -$0.54, representing a year-over-year change of 69.3% [5]

Novavax (NVAX) closed at $7.26 in the latest trading session, marking a -1.76% move from the prior day. The stock fell short of the S&P 500, which registered a loss of 0.33% for the day. Meanwhile, the Dow lost 0.37%, and the Nasdaq, a tech-heavy index, lost 0.53%.Prior to today's trading, shares of the vaccine maker had gained 0.96% over the past month. This has outpaced the Medical sector's loss of 3.24% and the S&P 500's loss of 4.03% in that time.The upcoming earnings release of Novavax will be of great ...

Buying stocks after they have lost significant market value can lead to excellent returns in the long run, but only if the company in question can reverse its fortunes.Sometimes, corporations lag the broader market for good reasons. Maybe they aren't delivering strong financial results, or their prospects look increasingly dim. Investors want to stay away from these stocks even when they look like they hit rock bottom since they are unlikely to recover and deliver solid returns.With that in mind, let's cons ...

Dr. Young made the decision to resign from the board effective March 10, 2025. He has served on Novavax's board since 2010 and as Chair since 2011. During his tenure, the Company acquired Isconova and the Matrix-M™ adjuvant, now a key component of its technology platform. Novavax also earned global approvals for and commercialized its first vaccine ever for COVID-19, ramping up quickly to meet the demands of the global pandemic. Dr. Young helped to guide the Company through the partnership with Sanofi in 20 ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts ...

Viking Therapeutics (VKTX 3.06%) and Novavax (NVAX -3.55%) were two of the big winners in the biotech industry last year. Both companies saw their shares rise significantly; the former had exciting clinical progress, while the latter signed a lucrative deal with a biotech giant that had Wall Street cheering.Are these stocks worth buying in 2025 after their strong performance last year? My view is that only one of them looks attractive, while the other isn't worth the trouble. Here's why.The biotech stock to ...

GAITHERSBURG, Md., Feb. 27, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), today announced that the management team will participate in the following upcoming investor conferences: TD Cowen 45th Annual Health Care Conference: Fireside Chat Date: Tuesday, March 4, 2025 Time: 9:10 – 9:40 a.m. Eastern Time (ET) Location: Boston, MA   Conference Event: Investor Meetings Date: Tuesday, March 4, 2025 Leerink Partners 2025 Global Healthcare Conference: Presentation ...

Novavax (NVAX) incurred a fourth-quarter 2024 loss of 51 cents per share, narrower than the Zacks Consensus Estimate of a loss of 75 cents. In the year-ago quarter, the company reported a loss of $1.44 per share.Revenues in the quarter amounted to $88.3 million, which beat the Zacks Consensus Estimate of $86 million. However, the top line declined 70% on a year-over-year basis.See the Zacks Earnings Calendar to stay ahead of market-making news.Year to date, Novavax stock has declined 9% against the industry ...

Novavax, Inc. (NASDAQ:NVAX) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Luis Sanay - Vice President, Investor Relations John Jacobs - President and Chief Executive Officer Ruxandra Draghia-Akli - Executive Vice President, Head of Research and Development John Trizzino - President and Chief Operating Officer Jim Kelly - Executive Vice President, Chief Financial Officer and Treasurer Robert Walker - Senior Vice President and Chief Medical Officer Conference Call Particip ...